Associate Professor of Pediatrics with Tenure, RWJ Medical School
Associate Professor of Epidemiology, Rutgers School of Public Health
Center for Pharmacoepidemiology and Treatment Science (PETS), Institute for Health, Health Care Policy and Aging Research
daniel.horton@rutgers.edu
Clinic 732-235-4980
Office 848-932-4607
Dr. Daniel Horton (MSCE, Clinical Epidemiology, University of Pennsylvania, 2015; MD, Harvard Medical School, 2008; AB, Harvard College, 2001) is a board-certified pediatric rheumatologist and physician-scientist with research training in pharmacoepidemiology. At Rutgers, he is an Associate Professor of Pediatrics and Epidemiology, Chancellor’s Scholar, founding core faculty member of the Center for Pharmacoepidemiology and Treatment Science (PETS) at the Institute for Health, Health Care Policy and Aging Research (IFH), and Faculty Director of the IFH Survey / Data Core. He is also a founding steering member of the Rutgers Child Health & Well-Being Research Group and Co-Leader of the Team Science Core of NJ ACTS (CTSA). Within the Department of Pediatrics at Rutgers Robert Wood Johnson Medical School, he belongs jointly to the Divisions of Population Health, Quality, and Implementation Sciences (PopQuIS) and Pediatric Rheumatology, and he is Co-Chair of the Pediatric Resident Scholarly Oversight Committee. He also is adjunct faculty in the Department of Biostatistics and Epidemiology at the Rutgers School of Public Health, where he directs the Clinical Epidemiology Certificate Program. Dr. Horton’s research focuses on the utilization, effectiveness, and safety of drugs in large pediatric populations and the origins and management of juvenile idiopathic arthritis (JIA), with a focus on the microbiome and microbiome-altering medicines. He has also been involved in a variety of research efforts on COVID-19 and multisystem inflammatory syndrome in children. Dr. Horton has experience performing large retrospective studies using administrative claims, electronic health records, and other health databases as well as prospective clinical, translational, and mixed methods research. His research has been funded by the National Institutes of Health (NIAMS, NIAID, NCATS, NICHD) and several research foundations. Dr. Horton serves as Consultant to the Food and Drug Administration Drug Safety and Risk Management Advisory Committee as well as Associate Editor for Pharmacoepidemiology and Drug Safety.
